Annual breast cancer screening beginning at 40 saves lives
Annual breast cancer screening beginning at age 40 and continuing to at least age 79 results in the highest reduction in mortality with minimal risks, according to a… read more.
Annual breast cancer screening beginning at age 40 and continuing to at least age 79 results in the highest reduction in mortality with minimal risks, according to a… read more.
Positive high-level results from the LAURA Phase III trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) for patients… read more.
The biologics license application (BLA) for the interleukin (IL)-2–based immunotherapy denileukin diftitox (Lymphir) in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL) following at least 1 prior… read more.
Delays in diagnosing melanoma due to Covid-19 lockdown may have contributed to over 100,000 years of life lost across Europe and over £6bn in costs, mainly indirectly due… read more.
The Blood Cancer Healing Center, located at 3229 Burnet Avenue in Uptown Cincinnati, is poised to redefine care standards by offering comprehensive patient support and innovative treatments under… read more.
New research by Joseph Reiner and colleagues at Virginia Commonwealth University shows promise for a urine-based test for ovarian cancer. Reiner will present their research at the 68th Biophysical… read more.
Bristol Myers Squibb announced two regulatory acceptances for applications for; i. neoadjuvant Opdivo (nivolumab) with chemotherapy followed by surgery and ii. adjuvant Opdivo for the perioperative treatment of… read more.
Bristol Myers Squibb announced three regulatory acceptances from the FDA and Japan’s Ministry of Health, Labour and Welfare (MHLW) for Breyanzi (lisocabtagene maraleucel) In the U.S., the FDA… read more.
Kite, a Gilead Company announced that the FDA has approved a manufacturing process change resulting in a shorter manufacturing time for Yescarta (axicabtagene ciloleucel). With this approval, Kite’s… read more.
Novocure announced that its Premarket Approval (PMA) application seeking approval for the use of Tumor Treating Fields (TTFields) therapy together with standard systemic therapies for the treatment of… read more.
Kite, a Gilead Company announced data from follow-up analyses of three studies of Yescarta (axicabtagene ciloleucel) that demonstrate the long-term survival potential for patients living with several sub-types… read more.
Screening for colon cancer reduces cancer rates by substantially more than previous analyses of randomized trials suggest, according to a study co-authored by an MIT economist that takes… read more.
Advertisment